SINGAPORE, June 18, 2012 /PRNewswire/ --
Vela Diagnostics has been unveiled as a new global player in the IVD world.
The Singapore headquartered Group, which already opened sites in New Jersey and Hamburg, has announced that its menu of workflow systems and test kits will be launched progressively from Q3 2012.
"VelaDx stands for a broad and nimble menu of products in Molecular PCR based Diagnostics," said the Group's CEO Michael Tillmann. "Our automated workflow will enable hospitals and labs to handle a broader range of tests on a single platform. Lab professionals will be able to do more, faster but with less complexity and higher efficiency."
The Company will provide an integrated automated RNA/DNA extraction and detection workflow on Vela's own "Sentosa" workflow. VelaDx tests will offer more than 30 test grouped in panels covering Microbiology, Oncology and Infectious Diseases.
The test kits are successfully transitioning into Production and QC testing, and will be ready for commercialization in selected Asian and European markets from Q3 2012. The Company is also seeking regulatory approval in the US and other markets.
About Vela Diagnostics
VelaDx provides a broad menu of molecular diagnostic tests, consolidated on its automated "Sentosa" workflow system. The Group was incorporated by an industry experienced management team in 2011 with the vision of providing in-vitro diagnostic solutions for customers to achieve improved patient management. VelaDx is a privately owned Group of Companies headquartered in Singapore. The Asia Pacific, European and North American commercial operations of the Group are based in Singapore, Hamburg and New Jersey, respectively. VelaDx also operates R&D sites in Singapore and New Jersey in addition to a Global Manufacturing facility in Singapore. For more information, please visit us at http://www.veladx.com
Dr. Peter Matthiesen
Vela Diagnostics Germany GmbH
SOURCE Vela Diagnostics